Harauchi Satoe, Osawa Takashi, Kubono Naoko, Itoh Hiroaki, Naito Takafumi, Kawakami Junichi
Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
J Infect Chemother. 2017 Jul;23(7):446-451. doi: 10.1016/j.jiac.2017.03.015. Epub 2017 Apr 19.
Few clinical studies have determined the quantitative transfer of vaginal chloramphenicol to circulating blood in pregnant women. This study aimed to evaluate the plasma concentration of chloramphenicol in pregnant women treated with trans-vaginal tablets and its relationship with maternal background and neonatal health. Thirty-seven pregnant women treated with 100 mg of trans-vaginal chloramphenicol once daily for bacterial vaginosis and its suspected case were enrolled. The plasma concentration of chloramphenicol was determined using liquid chromatography coupled to tandem mass spectrometry at day 2 or later after starting the medication. The correlations between the maternal plasma concentration of chloramphenicol and the background and neonatal health at birth were investigated. Chloramphenicol was detected from all maternal plasma specimens and its concentration ranged from 0.043 to 73.1 ng/mL. The plasma concentration of chloramphenicol declined significantly with the administration period. The plasma concentration of chloramphenicol was lower at the second than the first blood sampling. No correlations were observed between the maternal plasma concentration of chloramphenicol and background such as number of previous births, gestational age at dosing, and clinical laboratory data. Neonatal infant health parameters such as birth-weight, Apgar score at birth, and gestational age at the time of childbearing were not related to the maternal plasma concentration of chloramphenicol. Vaginal chloramphenicol transfers to circulating blood in pregnant women. The maternal plasma concentration of chloramphenicol varied markedly and was associated with the administration day, but not with maternal background or her neonatal health.
很少有临床研究确定孕妇阴道用氯霉素向循环血液中的定量转移情况。本研究旨在评估经阴道片剂治疗的孕妇体内氯霉素的血浆浓度及其与母亲背景和新生儿健康的关系。纳入了37名因细菌性阴道病及其疑似病例而每天一次接受100mg经阴道氯霉素治疗的孕妇。在开始用药后第2天或之后，使用液相色谱-串联质谱法测定氯霉素的血浆浓度。研究了母亲血浆中氯霉素浓度与出生时的母亲背景和新生儿健康之间的相关性。在所有母亲血浆样本中均检测到氯霉素，其浓度范围为0.043至73.1ng/mL。氯霉素的血浆浓度随给药时间显著下降。第二次采血时氯霉素的血浆浓度低于第一次。未观察到母亲血浆中氯霉素浓度与诸如既往分娩次数、给药时的孕周和临床实验室数据等背景之间存在相关性。新生儿健康参数如出生体重、出生时的阿氏评分和分娩时的孕周与母亲血浆中氯霉素浓度无关。阴道用氯霉素可转移至孕妇的循环血液中。母亲血浆中氯霉素浓度变化显著，与给药天数有关，但与母亲背景或其新生儿健康无关。
